Comparing SG&A Expenses: Merck & Co., Inc. vs MiMedx Group, Inc. Trends and Insights

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals and biotechnology, understanding financial trends is crucial. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Merck & Co., Inc. and MiMedx Group, Inc., from 2014 to 2023.

Merck, a pharmaceutical giant, consistently reported SG&A expenses in the range of $9 billion to $11 billion annually. Notably, their expenses peaked in 2014 and saw a slight decline, only to rise again by 2023. This trend reflects Merck's strategic investments in marketing and administration, crucial for maintaining its market position.

In contrast, MiMedx, a smaller biotech firm, exhibited a different trajectory. Starting with expenses under $100 million in 2014, they experienced a steady increase, reaching over $200 million by 2023. This growth underscores MiMedx's expanding operations and market reach.

These insights reveal the dynamic nature of SG&A expenses and their impact on corporate strategy.